Comparison of Two Accelerated Vaccination Campaigns Against COVID-19; from 16 to 31 December 2021 and from 23 February to 13 March 2022 in the Republic of Guinea

Résumé fourni par la source

Introduction: COVID-19 is an infectious respiratory disease that can be fatal in patients weakened by age or another chronic illness. Several means have been used to prevent this disease, including vaccination against COVID-19, which has also enabled us to protect the population against COVID-19. It began on 4 March 2021 in Guinea with front-line staff, with vulnerable people, those aged 60 and over, being the first beneficiaries. The low vaccination coverage of 3.5% led the Ministry of Health to organize two campaigns to accelerate vaccination against COVID-19 throughout the country. The first ran from 16 to 31 December 2021 and the second from 23 February to 13 March 2022. The aim of our study was to compare these two accelerated vaccination campaigns against COVID-19 to check whether all the recommendations had been considered. Methodology: This was a retrospective, analytical, cross-sectional study comparing two accelerated vaccination campaigns against COVID-19, carried out from 10 August to 20 September 2022 and involving all vaccinated persons entered in the DHIS2 software during the two accelerated vaccination campaigns against COVID-19: organized from 16 to 31 December 2021 and from 23 February to 13 March 2022 in the Republic of Guinea. The data collected in the two COVID-19 vaccination databases were exported using Excel and analyzed using SPSS version 24. Results: Our study enabled us to deduce that during the second campaign, vaccination coverage statistically doubled, that there was more vaccine available with the introduction of a new vaccine (Moderna), and that more MAPIs were notified (627) compared with (269) during the first campaign, all of which were light. The seizure rate was 23% compared with 13% in the first campaign. Conclusion: At the end of our study, we found that during the second campaign: Vaccination coverage improved, the number of MAPIs notified increased, the number of vaccines was more available in terms of quality and quantity, and there was an improvement in data entry. These results will enable us to prepare better for future campaigns.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.